Enterprise Value

0.00

Cash

528.4M

Avg Qtr Burn

N/A

Short % of Float

0.00%

Insider Ownership

0.00%

Institutional Own.

0.01%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tazverik (Tazemetostat ) Details
NHL (Non-Hodgkins Lymphoma), R/R FL (Relapsed or Refractory Follicular Lymphoma) and ES (Epithelioid Sarcoma)

Approved

Quarterly sales

Onivyde Details
Cancer, Pancreatic cancer, Carcinoma

Approved

Quarterly sales

Bylvay (Odevixibat) (ileal bile acid transport inhibitor) Details
Progressive familial intrahepatic cholestasis

Approved

Quarterly sales

Approved

Quarterly sales

Sohonos (Palovarotene) Details
Genetic disorder, Fibrodysplasia ossificans progressiva, Rare genetic disease

Approved

Quarterly sales

Elafibranor (dual α,δ PPAR agonist) Details
Primary biliary cholangitis, Cholestatic Liver Disease

PDUFA

Approval decision

Phase 3

Data readout

Phase 3

Update

Cabometyx + atezolizumab Details
Cancer, Prostate cancer

Phase 3

Update